Clinical trials: Breast Tissue Accessory
Breast Cancer
Single Dose Partial Breast Radiotherapy
This study seeks to determine the maximum tolerated dose of a single-dose partial breast radiation given before lumpectomy using a radiosurgery technique.
- Trial name
- RSU (NCT00944528)
- Testing
- Radiosurgery
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Duke University
Solid Tumors
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with…
- Trial name
- NCT02711137
- Testing
- INCB057643, Gemcitabine, Paclitaxel
- Where
- 18 sites in United States, Belgium and 1 more
- Volunteers
- 137 people
- Sponsor
- Incyte Corporation
Respiratory Function, Breast Reconstruction
The Effect of Breast Reconstruction Surgery Using Tissue Expanders on Respiratory Functions
This study evaluates the effect of breast reconstruction surgery on respiratory functions. 45 patients elected for unilateral or bilateral breast reconstruction surgery will go through respiratory function examinations a month…
- Trial name
- NCT02491762
- Testing
- respiratory function tests
- Where
- Israel
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Yaron Har-Shai
Accessory; Breast Tissue
Monitoring Functional Variation in the Breast During Menstrual Cycle by Using Diffuse Optical Spectroscopy
The purpose of this study is to do determine the changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy.
- Trial name
- NCT00540306
- Testing
- Diffuse Optical Spectroscopy
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Accessory; Breast Tissue
Measurements of Breast Tissue Optical Properties
Approximately twelve percent of the women in the United States will develop breast cancer, the most common form of cancer affecting women, with 183,000 new cases projected for 1995.
- Trial name
- NCT00540540
- Testing
- Diffuse Optical Spectroscopy
- Where
- 4 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, Irvine
Breast Tissue Accessory, Breast Cancer
Motiva Flora Tissue Expander PMCF
The Motiva Flora® Tissue Expander clinical study (hereafter Motiva Flora® TE study) is a 6-month, open-label, prospective, multicentre post-marketing follow-up study designed to confirm the Safety and Effectiveness/Performance of…
- Trial name
- NCT05447988
- Testing
- Breast Tissue Expander
- Where
- 5 sites in Chile, Costa Rica and 2 more
- Volunteers
- 136 people
- Sponsor
- Establishment Labs
Breast Cancer
Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.
The potential consequences after breast cancer surgery are joint pain and sensitive disorders, the main sign of which is alterations in shoulder mobility.
- Trial name
- NCT02366793
- Testing
- Accessory joint mobilization, Nerve mobilization
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Alcala
Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma Stage IV
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT).
- Conditions
- Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma Stage IV, Lobular Breast Carcinoma, Lobular Breast Carcinoma Stage IV
- Trial name
- NCT05837767
- Testing
- Palliative radiotherapy
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Cancer, Ovarian Cancer
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.
- Conditions
- Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer
- Trial name
- NCT03667716
- Testing
- COM701, COM701 with Opdivo (Nivolumab).
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- Compugen Ltd
NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC)
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)
This is a study to determine the recommended dose of birabresib (MK-8628)(formerly known as OTX015) for further studies in participants with advanced nuclear protein in testis (NUT) midline carcinoma (NMC), triple negative breast…
- Conditions
- NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC), Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC)
- Trial name
- NCT02698176
- Testing
- Birabresib
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Positron Emission Mammography (PEM) Biopsy Accessory for the Diagnosis of Breast Cancer
The purpose of this research study is to evaluate how well the Stereo Navigator Biopsy Accessory for the PEM Flex solo II PET Scanner works for performing breast biopsy on suspicious lesions.
- Trial name
- NCT00981812
- Testing
- PEM Breast Biopsy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
NUT Midline Carcinoma, Triple Negative Breast Cancer
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
Open-label, phase I, non-randomized, multicentric study of single-agent birabresib (MK-8628) (formerly known as OTX015) administered according to two distinct regimens to participants with selected advanced tumors.
- Conditions
- NUT Midline Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation, Castrate-resistant Prostate Cancer
- Trial name
- NCT02259114
- Testing
- Birabresib
- Volunteers
- 47 people
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Accessory; Breast Tissue
Development of a Quantitative Tissue Optical Index of Breast Density For Prediction of Hormone Therapy Response
The purpose of this research study is to investigate whether breast density measured by a safe, painless imaging method (called Diffuse Optical Spectroscopic Imaging - DOSI) can detect the decrease of breast density in subjects…
- Trial name
- NCT01773551
- Testing
- Breast Density
- Where
- 4 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, Irvine
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Breast Cancer
The Comparison Between M-E-BCS and C-O-BCS.
This study is a multicenter, open-label, randomized controlled trial. The study aims to evaluate differences in operative efficiency (e.g., operative time), economic effect, surgical safety (e.g., surgical complication rates)…
- Trial name
- MECO (NCT07539545)
- Testing
- Minimal accessory-incision-assisted endoscopic breast-conserving surgery, Conventional open breast-conserving surgery
- Where
- China
- Volunteers
- 1,366 people
- Sponsor
- Du Zhenggui
Breast Neoplasms
Sensitivity of Organoids to Predict Treatment Outcome in Breast Cancer Metastases
The aim of the study is to generate patient-derived organoids (PDOs) from brain resection or biopsied extra-cranial metastases. The preliminary data collected will be used to assess the ability of PDOs to predict patients'…
- Trial name
- PDO (NCT06468124)
- Where
- 2 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- King's College London
Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine ditartrate, work in different ways to stop the growth of tumor…
- Conditions
- Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma, Male Breast Cancer, Malignant Paraganglioma
- Trial name
- NCT01155258
- Testing
- temsirolimus, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Southern California
Malignant Tumor of Breast
Lifestyles and Breast Cancer
Background: In Spain, 1 out of every 11 women will have a breast cancer before the age of 85 years and breast cancer is the leading cause of potential years of life lost.
- Trial name
- LifeBreast (NCT04174391)
- Testing
- Mediterranean diet supplemented with extra-virgin olive oil, Low-fat diet
- Where
- 4 sites in Spain
- Volunteers
- 766 people
- Sponsor
- University of Navarra